Picture of Effector Therapeutics logo

EFTR — Effector Therapeutics News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

eFFECTOR Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

* eFFECTOR Therapeutics Inc  EFTR.OQ   EFTR.O  is expected
to show
no change in quarterly revenue when it reports  results on May 8
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for eFFECTOR
Therapeutics Inc
is for a loss of 14 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for eFFECTOR
Therapeutics Inc is $7​, above​ its last closing price of $0.50.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.23       -0.24      -0.22     Beat    7.6
 Sep. 30 2022  -0.21       -0.21      -0.23     Missed  -7.6
 Jun. 30 2022  -0.16       -0.16      -0.17     Missed  -5.5​
 Mar. 31 2022  -0.24       -0.24      0.07      Beat    129.5
 ​​Dec.                    -0.24      0.44      Beat    283.2
 31 2021                                                
 Sep. 30 2021  -0.25       -0.20      0.42      Beat    313.6​
 This summary was machine generated May 5 at 13:48 GMT.  All
figures in US dollars  unless otherwise stated

Recent news on Effector Therapeutics

See all news